Sickle cell anemia is one of a group of inherited disorders known as sickle cell disease. It affects the shape of red blood ...

Challenges persist despite promising advance In January 2025, the National Institute for Health and Care Excellence (NICE) approved the use of the gene editing therapy exagamglogene autotemcel ...

CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 ...

Sickle cell disease is an inherited blood disorder that primarily affects Black and Hispanic people. There are significant ...

Daniel Cressy yawned, tired after three days of watching a machine pull blood out of his body, extract his stem cells and ...

If successful, the access model for sickle cell disease gene therapies could serve as a blueprint for other such treatments ...

Daniel Cressy will be the first patient in Louisiana to complete the gene therapy treatment for sickle cell disease.

The primary safety risks associated with gene therapy include immune reactions and off-target effects in unintended organs, ...

Genome editing, also referred to as gene editing, is a group of technologies that enables scientists to change an organism’s ...

Daniel Cressy has dreams of becoming a pilot one day, but was told the only way he could get a license to fly is if his ...

Oregon will initially focus on providing lower-cost therapies for people living with sickle cell disease, a genetic blood ...

The multiagent AI system, dubbed “CRISPR-GPT,” is designed to interact and reason with human users as they execute ...